Drug Profile


Alternative Names: Anti-IL-5Rα Mab; Anti-IL5Ra monoclonal antibody - MediImmune; Anti-interleukin-5 receptor alpha monoclonal antibody - MedImmune; BIW-8405; BIW-8405-IL-5R; KHK 4563; MEDI-563

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Kyowa Hakko
  • Developer AstraZeneca; Kyowa Hakko; Kyowa Hakko Kirin; MedImmune
  • Class Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Interleukin 5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Asthma; Chronic obstructive pulmonary disease
  • Phase II Hypereosinophilic syndrome; Rhinosinusitis

Most Recent Events

  • 04 Jan 2017 AstraZeneca in collaboration with National Jewish health plans the phase II BITE trial for Asthma (NCT03010436)
  • 01 Jan 2017 AstraZeneca completes a phase III trial in Asthma (Adjunctive treatment, In adolescents) in USA (SC) (NCT02814643)
  • 01 Jan 2017 AstraZeneca initiates a phase I pharmacokinetics trial in Healthy volunteers in Germany (SC) (NCT02968914)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top